Clinical and virological characteristics of chronic hepatitis B with concurrent hepatitis B E antigen and antibody detection

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01345.x/abstract

Clinical and virological characteristics of chronic hepatitis B with concurrent

hepatitis B E antigen and antibody detection

J. Wang, B. Zhou, Q. Lai, Y. Wang, G. Shen, Z. Wang, J. Chen, J. Hou

Article first published online: 16 JUL 2010

DOI: 10.1111/j.1365-2893.2010.01345.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 9, pages 646–652, September 2011

Summary.  The concurrent detection of hepatitis B e antigen (HBeAg) and its

corresponding antibody (anti-HBe) in patients with chronic hepatitis B virus

(HBV) infection is well established but the clinical features remain poorly

understood. Demographic information, clinical and laboratory data were collected

from 1624 consecutive inpatient records of patients with chronic hepatitis B.

Viral genotype, basic core promoter and precore mutations were determined by

direct sequencing. In vitro HBeAg and anti-HBe binding experiments were

conducted with three pairs of HBeAg-positive and anti-HBe-positive serum

samples, which were mixed at variable ratios and incubated at 37 °C for 3–24

h. Of the 1624 chronic patients, 169 (10.4%) had concurrent HBeAg and anti-HBe

positivity, and this was associated with intermediate age and HBV-DNA load,

higher alanine aminotransferase level and more pronounced liver damage compared

with HBeAg-positive or anti-HBe-positive patients alone. HBeAg and anti-HBe

titres (median and interquartile range, S/CO) in the concurrent positive group

were 4.2 (1.8–9.6) and 0.54 (0.27–0.72), which were closer to their

respective cut-off values than those of HBeAg-positive or anti-HBe-positive

groups alone. For the cases successfully sequenced, 110/134 (82.1%) harboured

T1762/A1764 or/and A1896 mutants. The binding experiments showed that HBeAg and

anti-HBe could be concurrently observed provided an optimal ratio (HBeAg to

anti-HBe) was chosen. In antiviral treatment-naive patients, concurrence of

HBeAg and anti-HBe was not uncommon, and such patients had profound liver

disease. An optimal ratio between HBeAg and anti-HBe led to their concurrent

detection when sera were tested by sensitive assays.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01345.x/abstract

Clinical and virological characteristics of chronic hepatitis B with concurrent

hepatitis B E antigen and antibody detection

J. Wang, B. Zhou, Q. Lai, Y. Wang, G. Shen, Z. Wang, J. Chen, J. Hou

Article first published online: 16 JUL 2010

DOI: 10.1111/j.1365-2893.2010.01345.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 9, pages 646–652, September 2011

Summary.  The concurrent detection of hepatitis B e antigen (HBeAg) and its

corresponding antibody (anti-HBe) in patients with chronic hepatitis B virus

(HBV) infection is well established but the clinical features remain poorly

understood. Demographic information, clinical and laboratory data were collected

from 1624 consecutive inpatient records of patients with chronic hepatitis B.

Viral genotype, basic core promoter and precore mutations were determined by

direct sequencing. In vitro HBeAg and anti-HBe binding experiments were

conducted with three pairs of HBeAg-positive and anti-HBe-positive serum

samples, which were mixed at variable ratios and incubated at 37 °C for 3–24

h. Of the 1624 chronic patients, 169 (10.4%) had concurrent HBeAg and anti-HBe

positivity, and this was associated with intermediate age and HBV-DNA load,

higher alanine aminotransferase level and more pronounced liver damage compared

with HBeAg-positive or anti-HBe-positive patients alone. HBeAg and anti-HBe

titres (median and interquartile range, S/CO) in the concurrent positive group

were 4.2 (1.8–9.6) and 0.54 (0.27–0.72), which were closer to their

respective cut-off values than those of HBeAg-positive or anti-HBe-positive

groups alone. For the cases successfully sequenced, 110/134 (82.1%) harboured

T1762/A1764 or/and A1896 mutants. The binding experiments showed that HBeAg and

anti-HBe could be concurrently observed provided an optimal ratio (HBeAg to

anti-HBe) was chosen. In antiviral treatment-naive patients, concurrence of

HBeAg and anti-HBe was not uncommon, and such patients had profound liver

disease. An optimal ratio between HBeAg and anti-HBe led to their concurrent

detection when sera were tested by sensitive assays.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01345.x/abstract

Clinical and virological characteristics of chronic hepatitis B with concurrent

hepatitis B E antigen and antibody detection

J. Wang, B. Zhou, Q. Lai, Y. Wang, G. Shen, Z. Wang, J. Chen, J. Hou

Article first published online: 16 JUL 2010

DOI: 10.1111/j.1365-2893.2010.01345.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 9, pages 646–652, September 2011

Summary.  The concurrent detection of hepatitis B e antigen (HBeAg) and its

corresponding antibody (anti-HBe) in patients with chronic hepatitis B virus

(HBV) infection is well established but the clinical features remain poorly

understood. Demographic information, clinical and laboratory data were collected

from 1624 consecutive inpatient records of patients with chronic hepatitis B.

Viral genotype, basic core promoter and precore mutations were determined by

direct sequencing. In vitro HBeAg and anti-HBe binding experiments were

conducted with three pairs of HBeAg-positive and anti-HBe-positive serum

samples, which were mixed at variable ratios and incubated at 37 °C for 3–24

h. Of the 1624 chronic patients, 169 (10.4%) had concurrent HBeAg and anti-HBe

positivity, and this was associated with intermediate age and HBV-DNA load,

higher alanine aminotransferase level and more pronounced liver damage compared

with HBeAg-positive or anti-HBe-positive patients alone. HBeAg and anti-HBe

titres (median and interquartile range, S/CO) in the concurrent positive group

were 4.2 (1.8–9.6) and 0.54 (0.27–0.72), which were closer to their

respective cut-off values than those of HBeAg-positive or anti-HBe-positive

groups alone. For the cases successfully sequenced, 110/134 (82.1%) harboured

T1762/A1764 or/and A1896 mutants. The binding experiments showed that HBeAg and

anti-HBe could be concurrently observed provided an optimal ratio (HBeAg to

anti-HBe) was chosen. In antiviral treatment-naive patients, concurrence of

HBeAg and anti-HBe was not uncommon, and such patients had profound liver

disease. An optimal ratio between HBeAg and anti-HBe led to their concurrent

detection when sera were tested by sensitive assays.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2010.01345.x/abstract

Clinical and virological characteristics of chronic hepatitis B with concurrent

hepatitis B E antigen and antibody detection

J. Wang, B. Zhou, Q. Lai, Y. Wang, G. Shen, Z. Wang, J. Chen, J. Hou

Article first published online: 16 JUL 2010

DOI: 10.1111/j.1365-2893.2010.01345.x

© 2010 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Volume 18, Issue 9, pages 646–652, September 2011

Summary.  The concurrent detection of hepatitis B e antigen (HBeAg) and its

corresponding antibody (anti-HBe) in patients with chronic hepatitis B virus

(HBV) infection is well established but the clinical features remain poorly

understood. Demographic information, clinical and laboratory data were collected

from 1624 consecutive inpatient records of patients with chronic hepatitis B.

Viral genotype, basic core promoter and precore mutations were determined by

direct sequencing. In vitro HBeAg and anti-HBe binding experiments were

conducted with three pairs of HBeAg-positive and anti-HBe-positive serum

samples, which were mixed at variable ratios and incubated at 37 °C for 3–24

h. Of the 1624 chronic patients, 169 (10.4%) had concurrent HBeAg and anti-HBe

positivity, and this was associated with intermediate age and HBV-DNA load,

higher alanine aminotransferase level and more pronounced liver damage compared

with HBeAg-positive or anti-HBe-positive patients alone. HBeAg and anti-HBe

titres (median and interquartile range, S/CO) in the concurrent positive group

were 4.2 (1.8–9.6) and 0.54 (0.27–0.72), which were closer to their

respective cut-off values than those of HBeAg-positive or anti-HBe-positive

groups alone. For the cases successfully sequenced, 110/134 (82.1%) harboured

T1762/A1764 or/and A1896 mutants. The binding experiments showed that HBeAg and

anti-HBe could be concurrently observed provided an optimal ratio (HBeAg to

anti-HBe) was chosen. In antiviral treatment-naive patients, concurrence of

HBeAg and anti-HBe was not uncommon, and such patients had profound liver

disease. An optimal ratio between HBeAg and anti-HBe led to their concurrent

detection when sera were tested by sensitive assays.